NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Schizophrenia
In brief
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Key facts
- Study ID
- NCT07105098
- Run by
- Neurocrine Biosciences
- People needed
- 284
- Starts
- 2025-08-11
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-05-15
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Neurocrine Clinical Site — Kragujevac, Serbia (enrolling)
- Neurocrine Clinical Site — Garden Grove, California, United States (enrolling)
- Neurocrine Clinical Site — Riverside, California, United States (enrolling)
- Neurocrine Clinical Site — Atlanta, Georgia, United States (enrolling)
- Neurocrine Clinical Site — North Canton, Ohio, United States (enrolling)
- Neurocrine Clinical Site — Sliven, Bulgaria (enrolling)
- Neurocrine Clinical Site — Culver City, California, United States (enrolling)
- Neurocrine Clinical Site — Vratsa, Bulgaria (enrolling)
- Neurocrine Clinical Site — Győr, Hungary (enrolling)
- Neurocrine Clinical Site — Brasov, Romania (enrolling)
- Neurocrine Clinical Site — Brasov, Romania (enrolling)
- Neurocrine Clinical Site — Bucharest, Romania (enrolling)
- Neurocrine Clinical Site — Belgrade, Serbia (enrolling)
- Neurocrine Clinical Site — Gornja Toponica, Serbia (enrolling)
- Neurocrine Clinical Site — Veliko Tarnovo, Bulgaria
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.